Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab and Pembrolizumab in EGFR Mutant NSCLC
NCT04120454Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jun 2020
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Overall Response Rate at 2 years. Started Jun 2020; status: completed.
02
Drugs
ramucirumabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04120454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120454.